Eletriptan

證據等級: L5

預測適應症: 4 個

Eletriptan: From Acute Migraine to Migraine with Brainstem Aura

One-Sentence Summary

Eletriptan (Relpax) is a second-generation triptan and selective 5-HT1B/1D receptor agonist, originally developed and approved for the acute treatment of migraine with and without aura. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura (formerly known as basilar-type migraine), supported by 0 registered clinical trials targeting this specific subtype but 18 publications — including multiple RCTs and systematic reviews — examining eletriptan in relevant migraine populations. This prediction is mechanistically highly plausible, reflecting a reclassification of a historical contraindication rather than a true novel indication.

Quick Overview

Item	Content
Original Indication	Acute migraine (with or without aura)
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.99%
Evidence Level	L2
Taiwan Market Status	✗ Not Marketed
Number of Licenses (Taiwan)	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Eletriptan is a potent, selective 5-HT1B/1D receptor agonist (a “second-generation triptan”) with 6-fold greater affinity for the 5-HT1D receptor than sumatriptan and 3-fold greater affinity for 5-HT1B. Its primary mechanism involves selective constriction of intracranial vascular smooth muscle and inhibition of vasoactive peptide release (CGRP, Substance P) from trigeminal nerve endings, thereby interrupting the neurovascular cascade responsible for migraine pain.

Migraine with brainstem aura (MBA, previously called “basilar-type migraine” or “basilar migraine”) is a migraine subtype whose aura symptoms originate specifically from the brainstem or both occipital lobes — including dysarthria, vertigo, tinnitus, diplopia, or decreased consciousness. For many years, triptans were listed as contraindicated in this subtype due to theoretical concerns about vasoconstriction in the posterior circulation. However, the 2015 American Headache Society (AHS) evidence assessment explicitly re-examined this restriction and concluded that the contraindication lacked support from high-quality clinical evidence, and that triptans — including eletriptan — demonstrated clinical benefit in headache relief for this population.

The mechanistic link is therefore strong: eletriptan’s established 5-HT1B/1D receptor activity is directly relevant to the trigeminovascular pathway implicated in MBA, the same pathway targeted in standard migraine treatment. The prediction represents less of a “repurposing” and more of a label expansion into a previously excluded subpopulation — a scientifically well-grounded step that carries regulatory and safety dimensions warranting structured monitoring rather than fundamental mechanistic uncertainty.

Clinical Trial Evidence

Currently no clinical trials specifically registered for eletriptan in migraine with brainstem aura are available in ClinicalTrials.gov or ICTRP.

Context: The absence of dedicated trials for this subtype reflects the historical landscape — MBA patients were routinely excluded from triptan RCTs based on the now-reconsidered contraindication. This is a key gap that a targeted Phase 2/3 study could address.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25600718	2015	Systematic Review / Clinical Guideline	Headache	AHS evidence assessment of acute migraine pharmacotherapies; updated analysis of triptan evidence including re-evaluation of brainstem aura contraindication
12807526	2003	RCT	Cephalalgia	Double-blind, placebo-controlled RCT of eletriptan 40 mg in patients with prior inadequate response or intolerance to oral sumatriptan (n=446, with and without aura)
11687056	2001	Cochrane Systematic Review	Cochrane Database of Systematic Reviews	Original Cochrane review assessing eletriptan for acute migraine; established early evidence base for efficacy across aura subtypes
15469451	2004	RCT	European Journal of Neurology	RCT of eletriptan 80 mg administered during the aura phase in migraine with aura patients (IHS criteria); found no significant effect when taken during aura — relevant for timing strategy in MBA
11844898	2002	RCT (Active Comparator)	European Neurology	Double-blind RCT comparing eletriptan 40/80 mg vs. ergotamine/caffeine (Cafergot) and placebo; eletriptan 80 mg superior to both comparators in migraine with and without aura
17501848	2007	RCT / Patient-Reported Outcomes	Headache	Multidimensional functional impairment assessment in acute migraine treated with eletriptan; demonstrated improvements in work productivity and daily functioning
12498013	2002	Drug Profile / Review	Current Opinion in Investigational Drugs	Pharmacological profile of eletriptan; details 5-HT1B/1D receptor binding affinity comparisons with sumatriptan, zolmitriptan, and naratriptan
21028917	2010	Review	Paediatric Drugs	Review of triptan use in pediatric migraines including aura subtypes; highlights eletriptan’s place in treatment algorithms
15958097	2005	Single-blind Comparative Study	European Journal of Neurology	18-month comparison of five triptans including eletriptan 40 mg vs. placebo in patients with and without aura (n=42); assessed efficacy and tolerability across attacks
25155004	2014	Case Report	Revista Portuguesa de Cardiologia	Reports NSTEMI following eletriptan use in a patient with non-obstructive coronary artery disease and migraine with visual aura; highlights cardiovascular safety signal relevant to vascular subtypes including MBA

Taiwan Market Information

Eletriptan currently holds no approved Drug Identification Numbers (DINs) or marketing authorizations in Taiwan. The drug is classified as not marketed (未上市) in the Taiwan regulatory database.

Eletriptan (brand name Relpax®) is approved in multiple international markets including the United States (FDA), European Union (EMA), and Japan (PMDA) for the acute treatment of migraine with and without aura in adults. Any clinical use in Taiwan would require regulatory submission and approval from the Taiwan Food and Drug Administration (TFDA).

Safety Considerations

Specific safety data (label warnings, contraindications, and drug-drug interactions) for the Taiwan market authorization are not available in this Evidence Pack, as eletriptan is not currently marketed in Taiwan and the TFDA product monograph has not been retrieved.

The following safety signal is identified from the available literature:

Cardiovascular Risk: A published case report (PMID 25155004) documents a myocardial infarction following eletriptan use in a patient with underlying non-obstructive coronary artery disease. Vasoconstriction via 5-HT1B receptors on coronary vessels is a class-level concern for all triptans. This is particularly relevant for migraine with brainstem aura given the population’s potential overlap with posterior circulation vascular vulnerability.

For complete prescribing safety information, please refer to the current international product monograph (Pfizer Relpax® SmPC/USPI) pending local TFDA label review.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The 2015 AHS guideline reclassification provides credible, expert-reviewed support for using triptans — including eletriptan — in migraine with brainstem aura, and multiple high-quality RCTs establish eletriptan’s efficacy in the broader migraine-with-aura population. The mechanistic basis is directly aligned with eletriptan’s established pharmacology, making this a label-expansion scenario rather than a speculative repurposing. However, eletriptan is not currently marketed in Taiwan, and the historical vasoconstriction concern in posterior circulation requires prospective cardiovascular safety monitoring.

To proceed, the following is needed:

Regulatory pathway assessment: Evaluate requirements for TFDA import approval or new drug application for eletriptan in Taiwan, including reference to existing FDA/EMA approvals
TFDA product monograph retrieval: Download and parse the prescribing information from a reference market (e.g., US or EU) to complete the safety profile including full contraindication list, warnings, and drug interaction profile
Mechanism of action documentation: Retrieve complete MOA data from DrugBank (DB00216) to support the mechanistic rationale section in any regulatory dossier
Dedicated MBA cohort study: Design a prospective observational or controlled study specifically enrolling migraine with brainstem aura patients treated with eletriptan, with posterior circulation vascular event monitoring as a pre-specified safety endpoint
Cardiovascular screening protocol: Establish eligibility criteria to exclude patients with posterior circulation vascular disease, non-obstructive coronary artery disease, or hemiplegic migraine features prior to eletriptan use
Pharmacovigilance plan: Implement structured adverse event reporting for posterior circulation events (stroke, TIA, vasospasm) in any expanded-use program
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.